We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+30.58%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.89B
AUM Growth
+$619M
Cap. Flow
+$427M
Cap. Flow %
14.76%
Top 10 Hldgs %
55.7%
Holding
79
New
14
Increased
13
Reduced
2
Closed
4

Top Buys

Rank Stock Value
1
ITOS
iTeos Therapeutics
ITOS
+$117M
2
PMVP icon
PMV Pharmaceuticals
PMVP
+$83.5M
3
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$52.2M
4
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$48.2M
5
RLAY icon
Relay Therapeutics
RLAY
+$47.7M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$107M
2
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$36.3M
3
TRIL
Trillium Therapeutics Inc.
TRIL
+$33M
4
LABD icon
Direxion Daily S&P Biotech Bear 3X ETF
LABD
+$6.45M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$5.49M

Sector Composition

Rank Sector Weight
1 Healthcare 85.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IOVA icon
76
Iovance Biotherapeutics
IOVA
$1.82B
– –
-200,000
Closed -$5.49M
TRIL
77
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-4,075,000
Closed -$33M
PRNB
78
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
– –
-607,000
Closed -$36.3M
BLPH
79
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
– –
-98,809
Closed -$1.24M
1 2 3
4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q3 2020 Portfolio in Review

As of Q3 2020, Boxer Capital held 79 positions worth $2.89B, up 27% from $2.27B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Boxer Capital deployed $427M of net new capital in Q3 2020, opening 14 new positions and adding to 13 existing holdings. Its largest new stake was iTeos Therapeutics: 4,345,016 shares worth $107M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 86% a quarter earlier.

On the sell side, the largest reduction was Immunomedics Inc, an estimated $107M trimmed.

  • Boxer Capital's largest Q3 2020 buy was iTeos Therapeutics: 4,345,016 shares worth $107M.
  • Boxer Capital added most to Odonate Therapeutics, Inc. Common Stock in Q3 2020, an estimated $52.2M increase.
  • Boxer Capital's biggest Q3 2020 reduction was Immunomedics Inc, cutting an estimated $107M.
  • Boxer Capital fully exited Principia Biopharma Inc. Common Stock in Q3 2020, selling an estimated $36.3M.
  • Boxer Capital's ten largest holdings make up 56% of its $2.89B portfolio in Q3 2020.
  • Boxer Capital opened 14 new positions and closed 4 in Q3 2020.
  • Boxer Capital's portfolio value rose 27% quarter-over-quarter to $2.89B.

Based on Boxer Capital's 13F filing for Q3 2020, filed 16 Nov 2020.